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Abstract
The present study searched for a wide spectrum of features that might inﬂuence the survival of patients with
metastatic renal cell carcinoma treated with ﬁrst-line tyrosine kinase inhibitors. A total of 266 patients, who had
received sunitinib, pazopanib, or sorafenib, were evaluated using multivariable analysis and 2 bootstrap pro-
cedures. The results indicate that Fuhrman grade and the neutrophil-to-lymphocyte ratio are, in addition to
previously identiﬁed factors, independently associated with survival.
Background: The present study investigated the various features that might inﬂuence the overall survival (OS) of patients
with metastatic renal cell carcinoma (RCC) treated with ﬁrst-line tyrosine kinase inhibitors (TKIs). Patients and Methods: A
retrospective analysis was performed of consecutive patients with metastatic RCC, in whom treatment with a ﬁrst-line TKI
was initiated from January 2010 to December 2014, at the Department of Oncology, Military Institute of Medicine (Warsaw,
Poland). Cox proportional hazards regression was used to construct a prognostic model that included independent factors
for OS. We validated the model using 2 bootstrap procedures and calculation of the bias-corrected concordance index.
Results: Of the 266 patients included in the study, 201, 45, and 20 received sunitinib, pazopanib, and sorafenib, respec-
tively. The median OS for the whole cohort was 24.8 months (95% conﬁdence interval, 20.2-29.4 months). Six factors were
independently associated with poor survival: Eastern Cooperative Oncology Group performance status > 0 (P < .0001),
Fuhrman grade 3 to 4 (P< .0001), hemoglobin less than the lower limit of normal (P< .0001), lactate dehydrogenase greater
than the upper limit of normal (P ¼ .0011), neutrophil-to-lymphocyte ratio  4 (P < .0001), and > 2 metastatic sites (P ¼
.0012). The bias-corrected concordance index was 0.751. Conclusion: Fuhrman grade and neutrophil-to-lymphocyte ratio
are potential factors that affect the survival of patients with metastatic RCC treated with ﬁrst-line TKIs. The presented
prognostic model demonstrated satisfactory performance but requires external validation with a larger data set.
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article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Overall survival, Pazopanib, Prognostic factor, Sorafenib, SunitinibIntroduction
Renal cell carcinoma (RCC) is the most common type of kidney
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http://dx.doi.org/10.1016/j.clgc.2016.02.005associated death. Surgical resection of solitary or multiple metastases
should be considered in selected patients, because it can prolong cancer-
speciﬁc survival and overall survival (OS).2 Most patients with meta-
static disease, however, require systemic treatment, which is currently
based on molecular targeted therapies. The current lack of factors able
to predict the therapy-associated response and diversion of the natural
disease course has made the survival prognosis essential in patient
evaluation and further treatment. The prognostic models constructed
for this purpose divide patients into 3 risk groups, depending on the
number of factors inﬂuencing survival: Karnofsky or Eastern Cooper-
ative Oncology Group performance status (PS) (Memorial SloanClinical Genitourinary Cancer October 2016 - 457
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Fuhrman Grade and NLR in MRCCKettering Cancer Center [MSKCC],3 International Metastatic Renal-
Cell Carcinoma Database Consortium [IMDC],4 International Kid-
ney CancerWorkingGroup [IKCWG],5 and French6models), interval
from diagnosis to treatment (MSKCC, IMDC, and IKCWGmodels),
interval from diagnosis to metastasis (French model), the number of
metastatic sites (IKCWG and French models), liver metastasis (French
model), previous immunotherapy (IKCWG model), hemoglobin level
(MSKCC, IMDC, and IKCWG models), corrected or uncorrected
serum calcium level (MSKCC, IMDC, and IKCWG models),
neutrophil count (IMDC model), platelet count (IMDC model),
serum lactate dehydrogenase (LDH) level (MSKCC and IKCWG
models), white blood cell count (IKCWG model), and serum alkaline
phosphatase level (IKCWG model). Patients in the favorable and in-
termediate risk groups will strongly beneﬁt from tyrosine kinase in-
hibitors (TKIs), which have a leading role in ﬁrst-line and subsequent
therapies.7-10 Despite the high applicability of these models, a need for
improved management remains for patients receiving TKIs. Thus, we
retrospectively analyzed our patients’ medical records and searched for
clinical, pathologic, and radiologic features and laboratory results that
might inﬂuence survival in this group of patients.
Patients and Methods
Patients
The present study included consecutive patients who had
begun treatment with a ﬁrst-line TKI from January 2010 to
December 2014 at the Department of Oncology, Military
Institute of Medicine (Warsaw, Poland). The inclusion criteria
were as follows: (1) histologically conﬁrmed metastatic RCC of
any histopathologic subtype; (2) previous nephrectomy or
nephron-sparing surgery; (3) no previous radiotherapy; (4) no
other malignancies; and (5) no previous TKI therapy. Only those
patients treated using standard schedules and receiving 1 dose
of TKI were eligible. Those patients treated with immunotherapy
before the initiation of a TKI (ie, TKI therapy was second-line
systemic treatment) and/or who had initially undergone surgery
for metastatic disease (ie, resection of pulmonary metastases) were
also included. Patients who had received adjuvant therapy or an
investigational agent (ie, dovitinib) or an investigational combi-
nation (ie, sunitinib plus enzastaurin) at any time after diagnosis
were excluded.
The exact dates of deaths were obtained from the Polish National
Health Fund database (available at: https://csm-swd.nfz.gov.pl/). All
other information was gathered from the patients’ individual med-
ical records. The ethics committee of the Military Institute of
Medicine, Warsaw approved the study.
Outcomes
Because of the retrospective nature of the study, a sample size
calculation was not performed. The assessed outcome was OS,
deﬁned as the time from the initiation of ﬁrst-line TKI treatment to
death from any cause. The survival data were last updated on
September 1, 2015. Patients still alive at that date or lost to follow-
up were censored. The serum corrected calcium was calculated as
follows: total serum calcium þ 0.8  [4  serum albumin]. The
neutrophil-to-lymphocyte ratio (NLR) was deﬁned as the absolute
neutrophil count divided by the absolute lymphocyte count. TheClinical Genitourinary Cancer October 2016platelet-to-lymphocyte ratio (PLR) was deﬁned as the absolute
platelet count divided by the absolute lymphocyte count.
Statistical Analysis
The variables measured on an ordinal or a continuous scale were
converted to binary variables using predeﬁned cut points. The
Kaplan-Meier method was used to estimate the time-to-event curves
and median values and 95% conﬁdence intervals (CIs) for OS. The
median follow-up time was calculated using the Schemper and
Smith method.11 On univariable analysis, the factors were assessed
using the log-rank test; those that reached statistical signiﬁcance
were included in the multivariable analysis using the Cox propor-
tional hazard regression. A stepwise forward procedure with a sig-
niﬁcance level of .05 for entering and removing variables was used
to select the independent factors. The proportionality of hazards
assumption was checked in a 2-step procedure. In the ﬁrst step, a
graphic assessment with plots of natural logarithm (ln) (ln [sur-
vival]) versus the ln of survival time was performed separately for
each variable. In the second step, Schoenfeld residuals-based tests
were performed for each variable that entered the model, with
adjustment for other covariates and for the model as a whole.12
Next, the patients were divided into 3 groups according to the
number of unfavorable factors present for each patient.
Internal validation was performed using 2 bootstrap methods.13
Bootstrap samples were produced by taking samples from the
original data set using random sampling with replacement. In the
ﬁrst method, 500 new data sets were created and entered using the
same modelling process used to derive the ﬁnal model from the
original data set. The factors that appeared in > 40% of the
computed models were considered signiﬁcant. In the second
method, another 500 bootstrap samples were generated, and Cox
regression analysis was repeated for each sample, using the vari-
ables selected in the ﬁnal model. Parameter estimates, hazard
ratios, 95% CIs, and P values were produced and compared with
those from the model derived from the original data set. The
factors achieving P < .05 in this bootstrapping procedure were
considered signiﬁcant.
Discrimination is a measure of a model’s ability to separate
patients with different outcomes. To assess it, the concordance
index (c-index) and bias-corrected c-index for protecting against
overﬁtting during stepwise regression were calculated, with the
resulting values ranging from 0.5, representing no predictive ability,
to 1, representing perfect predictive ability to separate patients.14
P values less than the a level of .05 (2-sided) were considered
signiﬁcant for all analyses. Cases with missing data for any variable
were excluded from the analyses that involved that variable. Sta-
tistica, version 10 (StatSoft, Inc.) and R, version 3.2.2 (The R
Foundation for Statistical Computing) with the rms package
(available at: https://cran.r-project.org/web/packages/rms/index.
html) were used to perform the statistical analyses.
Results
Outcomes
A total of 266 patients were enrolled in the present study.
Detailed characteristics are listed in Table 1. Of these patients, 201,
45, and 20 had received sunitinib, pazopanib, and sorafenib,
Table 1 Patient Characteristics (n [ 266)
Variable n (%)
Age at start of TKI therapy (years)
Median 61
Range 22-85
Interval from diagnosis to TKI therapy
(mo)
Median 13.3
Range 0-242
Male gender 180 (67.7)
ECOG PS
0 117 (44.0)
1 143 (53.7)
2 6 (2.3)
Histologic type
Clear cell 248 (93.2)
Other 19 (6.8)
Sarcomatoid features 16 (6.0)
Fuhrman gradea
1 13 (5.4)
2 127 (53.2)
3 71 (29.7)
4 28 (11.7)
TNM T stageb
T1 45 (19.5)
T2 68 (29.6)
T3 109 (47.4)
T4 8 (3.5)
Previous immunotherapy 29 (10.9)
First-line TKI treatment
Sunitinib 201 (75.6)
Pazopanib 45 (16.9)
Sorafenib 20 (7.5)
Second-line treatment
None 159 (59.8)
Everolimus 97 (36.4)
Axitinib 10 (3.8)
Metastatic sites
1 54 (20.3)
2 76 (28.6)
>2 136 (51.1)
Table 1 Continued
Variable n (%)
Brain metastases 12 (4.5)
Hemoglobin <LLN 56 (21.0)
Serum albumin <LLNc 33 (13.0)
Serum corrected calcium> ULNc 28 (10.5)
Serum LDH> ULNd 67 (26.6)
Neutrophils> ULN 21 (7.9)
Platelets> ULN 37 (13.9)
NLR 3 124 (46.6)
NLR 4 65 (24.4)
PLR 150 145 (54.5)
PLR 200 92 (34.6)
Risk groups by IMDC modelc,e
Favorable 45 (17.7)
Intermediate 152 (59.9)
Poor 57 (22.4)
Abbreviations: ECOG ¼ Eastern Cooperative Oncology Group; IMDC ¼ International Metastatic
Renal Cell Carcinoma Database Consortium; LDH ¼ lactate dehydrogenase; LLN ¼ lower limit
of normal; NLR ¼ neutrophil-to-lymphocyte ratio; PLR ¼ platelet-to-lymphocyte ratio;
PS ¼ performance status; TKI ¼ tyrosine kinase inhibitor; ULN ¼ upper limit of normal.
aNumber of evaluated patients was 239.
bNumber of evaluated patients was 230.
cNumber of evaluated patients was 254.
dNumber of evaluated patients was 252.
eECOG PS > 0 considered as a risk factor instead of the original PS of > 1.
Figure 1 Kaplan-Meier Curve for Overall Survival for the Whole
Patient Cohort
Pawel Chrom et alrespectively. Also, 29 patients (10.9%) had received previous
immunotherapy and 107 (40.2%) second-line treatment. At the
conclusion of the survival data collection, 174 patients (65.4%) had
died. The median OS was 24.8 months (95% CI, 20.2-29.4
months; Figure 1), and the median follow-up time was 46.1 months
(95% CI, 41.2-51.0 months).
Model Building
We found that 22 factors signiﬁcantly inﬂuenced survival when
assessed on univariable analysis (Table 2). The median OS differedamong the treatment groups (24.8, 17.0, and 38.7 months for
sunitinib, pazopanib, and sorafenib, respectively); however, statis-
tical signiﬁcance was not reached (P ¼ .142). OS was not affected
by the use of previous immunotherapy (P ¼ .697).
On multivariable analysis, 6 factors were independently associ-
ated with poor survival: Eastern Cooperative Oncology Group
PS > 0 (P < .0001), Fuhrman grade 3 to 4 (P < .0001), hemo-
globin level less than the lower limit of normal (P < .0001), LDH
level greater than the upper limit of normal (P ¼ .0011), NLR  4
(P < .0001), and > 2 metastatic sites (P ¼ .0012; Table 3). The
proportionality of hazards assumption was met for each variable and
for the whole model (Table 4).Clinical Genitourinary Cancer October 2016 - 459
Table 2 Univariable Analysis Results for Overall Survival
Variable Patients Who Died (n) Total (n) Median OS (mo) Log-Rank P Value
Gender .872
Male 117 180 24.6
Female 57 86 24.8
Age (years) .266
<65 108 172 25.8
65 66 94 21.1
Interval from diagnosis to TKI
therapy (mo)
.001
12 82 137 32.4
<12 92 129 17.7
ECOG PS <.0001
0 58 117 40.1
>0 116 149 13.8
Histologic type .336
Clear cell 162 248 25.3
Other 12 18 11.2
Sarcomatoid features .019
No 162 250 25.3
Yes 12 16 9.1
Fuhrman grade <.0001
1-2 81 140 35.3
3-4 74 99 14.3
TNM T stage .104
T1-T2 72 113 28.1
T3-T4 80 117 18.6
Previous immunotherapy .697
No 154 237 24.6
Yes 20 29 32.3
First-line TKI treatment .142
Sunitinib 132 201 24.8
Pazopanib 29 45 17.0
Sorafenib 13 20 38.7
Metastatic sites (n) <.0001
1-2 69 130 35.3
>2 105 136 15.0
Local recurrence .001
No 126 201 27.8
Yes 48 65 13.7
Retroperitoneal/mediastinal
lymph node metastases
.0003
No 73 131 32.4
Yes 101 135 19.9
Lung metastases .003
No 42 75 40.0
Yes 132 191 20.6
Liver metastases .234
No 132 207 25.3
Yes 42 59 20.6
Pancreatic metastases .004
No 160 239 22.7
Yes 14 27 49.8
Fuhrman Grade and NLR in MRCC
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Table 2 Continued
Variable Patients Who Died (n) Total (n) Median OS (mo) Log-Rank P Value
Suprarenal gland metastases .341
No 140 221 25.2
Yes 34 45 17.0
Bone metastases .013
No 118 187 27.8
Yes 56 79 17.2
Contralateral kidney metastases .116
No 164 247 24.3
Yes 10 19 49.8
Brain metastases <.0001
No 164 254 25.8
Yes 10 12 5.3
Other soft tissues metastases .009
No 118 195 25.8
Yes 56 71 15.2
Hemoglobin <.0001
LLN 126 210 30.3
<LLN 48 56 6.8
Neutrophils <.0001
ULN 156 245 26.1
>ULN 18 21 7.0
Platelets .0004
ULN 145 229 27.5
>ULN 29 37 11.1
NLR <.0001
<3 84 142 35.1
3 90 124 15.2
NLR <.0001
<4 121 201 30.3
4 53 65 10.0
PLR <.0001
<150 63 121 40.1
150 111 145 14.2
PLR <.0001
<200 101 174 33.1
200 73 92 10.6
Serum LDH <.0001
ULN 107 185 28.1
>ULN 54 67 14.2
Serum creatinine .959
ULN 109 165 24.6
>ULN 65 101 25.2
Serum corrected calcium .026
ULN 142 226 25.8
>ULN 22 28 17.6
Serum albumin <.0001
LLN 135 221 27.7
<LLN 29 33 5.4
Abbreviations: ECOG ¼ Eastern Cooperative Oncology Group; LDH ¼ lactate dehydrogenase; LLN ¼ lower limit of normal; NLR ¼ neutrophil-to-lymphocyte ratio; OS ¼ overall survival;
PLR ¼ platelet-to-lymphocyte ratio; PS ¼ performance status; TKI ¼ tyrosine kinase inhibitor; ULN ¼ upper limit of normal.
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Table 3 Multivariable Analysis Results and Final Model (Total Patients [ 221)
Variable Parameter Estimate SE HR 95% CI P Value
Fuhrman grade 3-4 0.720 0.175 2.05 1.46-2.90 <.0001
ECOG PS> 0 0.883 0.185 2.42 1.68-3.48 <.0001
Metastatic sites> 2 0.588 0.182 1.80 1.26-2.57 .0012
Hemoglobin <LLN 0.962 0.198 2.62 1.77-3.86 <.0001
Serum LDH> ULN 0.618 0.190 1.86 1.28-2.69 .0011
NLR 4 0.771 0.192 2.16 1.49-3.15 .0001
Abbreviations: CI ¼ conﬁdence interval; ECOG ¼ Eastern Cooperative Oncology Group; HR ¼ hazard ratio; LDH ¼ lactate dehydrogenase; LLN ¼ lower limit of normal; NLR ¼ neutrophil-to-
lymphocyte ratio; PS ¼ performance status; SE ¼ standard error; ULN ¼ upper limit of normal.
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462 -After constructing the ﬁnal model, the patients were divided into 3
risk categories according to number of negative prognostic factors for
each patient. Patients with no factors were included in the favorable-
risk group (n ¼ 26; 11.4%) in which the median OS was not
reached. Patients with 1 or 2 factors were included in the
intermediate-risk group (n¼ 115; 50.4%), with a median OS of 35.9
months (95% CI, 27.9-43.9 months). Finally, patients with 3 to 6
factors were included in the poor-risk group (n ¼ 87; 38.2%), with
median OS of 8.8 months (95% CI, 5.6-12.0 months). The Kaplan-
Meier curves for each of the 3 risk groups are shown in Figure 2.
Model Validation
Both bootstrap methods conﬁrmed the appropriate construction
of the ﬁnal model. In the ﬁrst method, the factors derived from the
ﬁnal model appeared in> 40% of the 500 computed models. In the
second method, repeating Cox regression analysis on another 500
random samples entering the factors from the ﬁnal model resulted
in statistical signiﬁcance for each factor, with almost identical values
for the parameter estimates, hazard ratios, and 95% CIs. The
discrimination ability was highly satisfactory with a c-index and
bias-corrected c-index of 0.759 (95% CI, 0.706-0.812) and 0.751,
respectively (Table 4).
Discussion
TKIs have tremendously changed the perspective for patients
with metastatic RCC. The use of prognostic factors can help cli-
nicians determine the appropriate use of these types of drugs by
selecting the patients most likely to beneﬁt from them. The presentTable 4 Proportionality of Hazards Assumption Tests and Model Va
Variable
Schoenfeld
Residuals-Based
Test (P Value)
Frequency of Entry
(%)
Parame
Estima
Fuhrman grade 3-4 .289 90.4 0.698
ECOG PS >0 .064 96.4 0.888
Metastatic sites >2 .732 42.8 0.572
Hemoglobin <LLN .144 90.2 0.982
Serum LDH> ULN .493 82.4 0.672
NLR 4 .908 65.8 0.746
Global Schoenfeld residuals-based test, P ¼ .301; c-index ¼ 0.759; bias-corrected c-index ¼ 0.7
Abbreviations: CI ¼ conﬁdence interval; ECOG ¼ Eastern Cooperative Oncology Group; LDH ¼ l
PS ¼ performance status; ULN ¼ upper limit of normal.
Clinical Genitourinary Cancer October 2016study was conducted to discover whether the performance of the
current prognostic tools can be improved.
A general consensus has been reached that the PS remains one of
the most signiﬁcant prognostic factors in RCC.3-6,15 This has been
further strengthened by the identical conclusion from the present
study. The number of metastatic sites was reported in published
studies as a criterion in prognostic models.5,6 Similarly, the present
study found that involvement of metastatic processes in > 2 sites
was independently associated with a poor prognosis. However, the
presence of pancreatic metastases increased the median OS by
twofold on univariable analysis. This is another indication that
pancreatic metastases in RCC might be linked to a less aggressive
tumor phenotype.16
Other frequently reported risk factors, such as the time from
diagnosis to therapy initiation and the laboratory test ﬁndings, also
appeared in our study. However, only anemia and elevated LDH
were independently associated with a worse prognosis. The NLR
and PLR were also assessed as additional markers of inﬂammatory
response, which had been reported to have an impact on survival in
patients treated with TKIs for metastatic RCC.17-19 On univariable
analysis, an NLR of  3 and NLR of  4 and a PLR of  150 and
PLR of  200 were more signiﬁcant factors than the presence of
neutrophilia and thrombocytosis, respectively. Of these factors, an
NLR of  4 appeared in the ﬁnal model, suggesting it might be
even more relevant than neutrophilia; it is also a low-cost and widely
available prognostic biomarker.
The Fuhrman (nuclear) grade has been recognized as an inde-
pendent prognostic factor for all-stage and metastatic RCC.15,20 Inlidation
Bootstrap
ter
te HR 95% CI P Value
2.01 1.37-2.95 .001
2.43 1.70-3.47 <.001
1.77 1.23-2.56 .002
2.67 1.77-4.02 <.001
1.96 1.32-2.90 .001
2.11 1.43-3.12 <.001
51.
actate dehydrogenase; LLN ¼ lower limit of normal; NLR ¼ neutrophil-to-lymphocyte ratio;
Figure 2 Kaplan-Meier Curves for Overall Survival Stratiﬁed by
Risk Group
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associated with a poor outcome. This ﬁnding underlines the
necessity for further investigations on the relationship between
tumor biology and patient survival. The T stage of the TNM
classiﬁcation remains an important factor for the entire population
of patients with RCC15; however, it seems to lose signiﬁcance after
the development of metastases. The overrepresentation of patients
with clear cell histologic features in our study cohort made it
impossible to demonstrate whether the histologic subtype might
affect survival. The presence of sarcomatoid features is commonly
believed to worsen survival.21 However, this pathologic feature was
rarely observed; therefore, its negative effect might only be shown
on univariable analysis.
The present study’s generated model was sufﬁciently validated by
2 bootstrap procedures and a bias-corrected c-index of 0.751,
notably one of the highest reported in published studies on this
subject. However, the limitations of the present study included its
retrospective design, the restriction to a single center, and incom-
plete data collection. Moreover, a selection bias was observed
because we excluded patients without previous nephrectomy or
nephron-sparing surgery, favoring those with a better PS and
generally indicating our population was more ﬁt. The median OS
for the whole cohort was greater than the median survival reported
in larger population studies.22,23 However, 50.4% of patients were
in the intermediate-risk group and only 11.4% in the favorable-risk
group. The median OS for the poor-risk group was within the range
observed in previous, large cohort studies, although the median OS
for the intermediate-risk group was longer. This observation can be
explained by the Will Rogers phenomenon.24 Despite these disad-
vantages, our results are coherent with those from previous reports.
Of the 6 factors that emerged in the ﬁnal model, 4 are frequently
recognized as independent criteria for survival: PS, hemoglobin
level, LDH level, and the number of metastatic sites. In contrast,
the remaining 2—Fuhrman grade and NLR—have yet to be strictly
analyzed in the construction of the currently used prognostic
models.Conclusion
In summary, patients with metastatic RCC treated with ﬁrst-line
TKIs possess similar prognostic factors as previously reported in the
era of molecular targeted therapies. However, the results of our
study have shown that the Fuhrman grade and NLR should be
included when predicting patient survival. The model we have
proposed presents with satisfactory performance and potential but
requires external validation on a larger cohort of patients.
Clinical Practice Points
 Many studies have reported on models for predicting the survival
of patients with metastatic RCC treated with molecular targeted
therapies, including TKIs; however, the number of features
investigated by these studies has been limited.
 The present study reports a prognostic model that consists of 6
factors independently associated with survival. Four (PS, hemo-
globin, LDH, and the number of metastatic sites) have been
previously recognized as criteria for survival, and 2 (Fuhrman
grade and NLR) have yet to be strictly analyzed in the con-
struction of currently used prognostic models.
 Including the Fuhrman grade and NLR in the prognosis of
survival for patients with metastatic RCC could improve the
selection of patients most likely to beneﬁt from ﬁrst-line TKI
therapy.Disclosure
The authors declare that they have no competing interests.References
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